Objective Response Rate Clinical Trial
Official title:
Efficacy and Safety of Abraxane With Bevacizumab Biosimilar in Patients With Recurrent, Platinum-resistant Epithelial Ovarian Cancer：A Multi-center, Prospective, One-arm, Phase II Study
The study is a multi-center, prospective, one-arm, phase II clinical trial. It is tend to examine the safety and efficacy of combining abraxane(albumin-bound paclitaxel） and bevacizumab to treat patients with recurrent, platinum-resistant primary epithelial ovarian cancer, fallopian tube cancer or peritoneal carcinoma.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05760196 -
Radiotherapy Combined With PD-1 Inhibitor and GM-CSF for Advanced Recurrent Metastatic Head and Neck Tumors
|
Phase 2 | |
| Recruiting |
NCT04635956 -
Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas
|
Phase 2 | |
| Recruiting |
NCT04850560 -
Sequential Low-dose Decitabine With PD-1/CD28 CD19 CAR-T in Relapsed or Refractory B-cell Lymphoma
|
Phase 1 | |
| Recruiting |
NCT05310383 -
Tislelizumab and Radiotherapy for Recurrent Cervical Cancer
|
Phase 2 | |
| Suspended |
NCT05503108 -
Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer
|
Phase 3 | |
| Recruiting |
NCT06125834 -
Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy
|
Phase 2 | |
| Recruiting |
NCT03892577 -
Real-world Study for Patients With Advanced Hepatobiliary Tumors
|
||
| Recruiting |
NCT04664244 -
Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma
|
Phase 2 |